|
A Japanese version of
the National Institutes of Health Chronic Prostatitis
Symptom Index (NIH-CPSI, Okayama version) and the clinical
evaluation of cernitin pollen extract for chronic non-bacterial prostatitis
Monden K, Tsugawa M, Ninomiya Y, Ando E, Kumon H.
Department of Urology, Okayama University Graduate School of Medicine and
Dentistry,
Okayama, Japan.
PURPOSE: The chronic prostatitis syndromes are common disorders in urologic
practice and
present various clinical symptoms. The development of a chronic prostatitis
symptom index
appropriate for judgment of therapeutic effects is awaited since the
pathophysiology and
appropriate treatment are not well defined so far. We developed a Japanese
version of the
National Institutes of Health Chronic Prostatitis Symptoms Index (NIH-CPSI,
Okayama
version), and examined its usefulness. In addition, we evaluated clinical
effects of Cernitin for
chronic nonbacterial prostatitis using this symptom index.
SUBJECTS AND
METHODS: A total
of 87 patients including 34 patients with NIH chronic prostatitis category
III, 35 patients with
BPH and 18 patients for control group who visited the Department of Urology
at Okayama
University Medical School filled in the questionnaire of our Japanese
version of the NIH-CPSI to
compare the NIH-CPSI scores among three groups. Twenty-four patients with
NIH chronic
prostatitis category III (IIIa 16, IIIb 8) were treated with Cernitin
and the NIH-CPSI scores
were examined before and after its administration. RESULTS: The
pain/discomfort domain score
was 9.79 (mean) in the chronic prostatitis group, 1.66 in the BPH group and
0.39 in the control
group; that of the urinary symptom domain was 3.82, 3.29 and 0.72,
respectively; and that of the
quality of life (QOL) was 8.21, 4.17 and 1.39, respectively. The
pain/discomfort domain score
was significantly higher in the chronic prostatitis group than in the other
groups; the QOL
domain score was higher in the order of the chronic prostatitis group, the
BPH group and the
control group. In the chronic prostatitis group, there was a significant,
positive correlation
between the pain/discomfort domain score and that of the QOL, and between
the urinary
symptom domain score and that of the QOL. These results suggested the
usefulness of our
Japanese version of the NIH-CPSI as a parameter of the severity of chronic
prostatitis.
Examination of changes in the NIH-CPSI scores revealed that scores of the
items in all domains
were significantly lower 4 to 6 weeks after the start of administration of
Cernitin than those
obtained before the drug administration in patients with chronic prostatitis.
CONCLUSIONS: A
Japanese version of NIH-CPSI (Okayama version) accurately reflects clinical
symptoms and the
QOL in patients with chronic prostatitis. It seemed to be a useful and
appropriate system for
scoring symptoms of chronic prostatitis, indicating further studies on
translation, adaptation and
validation of the NIH-CPSI in Japan.
Publication Types:
• Clinical Trial
• Controlled Clinical Trial
PMID: 12056038 [PubMed - indexed for MEDLINE]
|
